SAA1 and hepatocellular carcinoma: Using pAAV-Saas-Sh and pAAV-Con C57BL/6 N mouse models with orthotopically implanted liver tumors derived from subcutaneous tumors (HCC cell line, Hep1-6; colon adenocarcinoma cell line, MC-38), we demonstrated that the specifically knockdown of Saa1 and Saa2 expression in hepatocytes by pAAV-Saas-Sh significantly inhibited primary and secondary liver tumor growth in vivo (1.31 ± 0.68 mL vs 0.44 ± 0.29 mL, P < 0.05 for Hep1-6 cell line; 1.52 ± 0.33 mL vs 0.53 ± 0.27 mL, P < 0.05 for MC-38 cell line; Fig. 6e, f; Supplementary information, Fig. S10h, i).